Literature DB >> 16273237

Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.

Masafumi Inoue1, Tetsuji Sawada, Yasutake Uchima, Kenjiro Kimura, Tamahiro Nishihara, Hiroaki Tanaka, Masakazu Yashiro, Nobuya Yamada, Masaichi Ohira, Kosei Hirakawa.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a unique type of serine protease inhibitor and one of the key regulators of tumor invasion and metastasis. The purpose of this study was to elucidate the effect of PAI-1 gene transfection on liver metastasis and its mechanism by using the human high liver metastasis pancreatic cancer cell line, SW1990. PAI-1-transfected SW1990 (SW/PAI-1) produced a significantly higher level of PAI-1 in supernatant than parental cells. While no difference was observed for the production of u-PA and u-PA activity in the supernatant, cell proliferation of SW/PAI-1 was slightly suppressed on the 7th day of incubation compared to parental cells. Cellular invasion, in vivo tumorigenesis in xenograft and liver metastasis were significantly suppressed in SW/PAI-1 cells compared to parental cells. The angiogenesis of xenograft by detecting microvascular density and the production of metastasis-related factors, such as VEGF and TGF-beta1, were also decreased in SW/PAI-1 cells. These findings suggested that PAI-1 gene transfection might have the ability to prevent the liver metastasis of pancreatic cancer by modulating angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273237

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

Review 1.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.

Authors:  Marta Helena Kubala; Yves Albert DeClerck
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

2.  Prostate cancer cell surface-associated keratin 8 and its implications for enhanced plasmin activity.

Authors:  Melissa Hirsch Kuchma; Joo Hee Kim; Mark T Muller; Philip A Arlen
Journal:  Protein J       Date:  2012-03       Impact factor: 2.371

3.  Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53.

Authors:  Sreerama Shetty; Praveenkumar Shetty; Steven Idell; Thirunavukkarasu Velusamy; Yashodhar P Bhandary; Rashmi S Shetty
Journal:  J Biol Chem       Date:  2008-05-09       Impact factor: 5.157

4.  Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer.

Authors:  Yu-Jing Huang; Marsha L Frazier; Nianxiang Zhang; Qian Liu; Chongjuan Wei
Journal:  Dig Dis Sci       Date:  2013-11-19       Impact factor: 3.199

5.  Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Wen-Jing Liu; Li Zhou; Zhi-Yong Liang; Wei-Xun Zhou; Lei You; Tai-Ping Zhang; Yu-Pei Zhao
Journal:  Chin Med J (Engl)       Date:  2018-12-20       Impact factor: 2.628

6.  PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208.

Authors:  Sandra Muñoz-Galván; Maria Rivero; Javier Peinado-Serrano; Julia Martinez-Pérez; M C Fernández-Fernández; María José Ortiz; José M García-Heredia; Amancio Carnero
Journal:  Cells       Date:  2020-04-25       Impact factor: 6.600

7.  Sustained postoperative plasma elevations of plasminogen activator inhibitor-1 following minimally invasive colorectal cancer resection.

Authors:  H M C Shantha Kumara; Poppy Addison; Dasuni N Gamage; Erica Pettke; Abhinit Shah; Xiaohong Yan; Vesna Cekic; Richard L Whelan
Journal:  Mol Clin Oncol       Date:  2021-12-08

8.  Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model.

Authors:  M Niedergethmann; F Alves; J K Neff; B Heidrich; N Aramin; L Li; C Pilarsky; R Grützmann; H Allgayer; S Post; N Gretz
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

Review 9.  Therapeutics targeting the fibrinolytic system.

Authors:  Haili Lin; Luning Xu; Shujuan Yu; Wanjin Hong; Mingdong Huang; Peng Xu
Journal:  Exp Mol Med       Date:  2020-03-09       Impact factor: 8.718

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.